NCT07591376Completed
A Reminder App to Improve Physical Activity During Radiotherapy for Lung Cancer - a Pre-study in Healthy Volunteers
Source: ClinicalTrials.gov · Last updated 15 May 2026
Brief summary (registry, in English)
Physical activity prior to and during chemo- and/or immunotherapy for lung cancer appears important. This may also be true for patients with lung cancer treated with radiation therapy. However, adherence to an exercise program sometimes may be challenging for the patients, particularly if they experience fatigue or other adverse events. The question arose whether an easy-to-use mobile app installed on the patient's smart phone reminding patients several times daily to perform a certain number of steps will have a positive effect on their physical activity during a course of radiation therapy. Such an app has been developed within the Interreg project HeAT (Health Advancing Technologies for Elderly). However, before this app can be tested in a prospective trial involving patients, its usability should to be evaluated by healthy volunteers. In the present prospective study, 30 healthy volunteers test and rate ten aspects related to the usability of the app. The healthy volunteers have to download a reminder app, which has been designed by the Lübeck based company Nextlabel Offene Handelsgesellschaft (OHG). After receiving the link for the download of the app from Nextlabel OHG by e-mail, the participants are asked to test the app and complete a questionnaire. They are asked to affirm or negate ten statements in three sections (download and installation, navigation, and content/functions) regarding the usability of the reminder app. The satisfaction rate represents the rate of participants who affirmed a statement. If this rate was \<60%, the reminder app was rated as not being useful. If the rate was between ≥60% but \<80%, the app was regarded useful but required further optimization regarding the corresponding section. In addition, iPhone and Android users are compared with respect to the satisfaction rates.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 5 May 2026
- Start date
- 19 Mar 2026
- Primary completion date
- 21 Apr 2026
- Lead sponsor
- University Hospital Schleswig-Holstein
- Diseases
- Lung cancer
- NCT number
- NCT07591376
What you commit to
- Study type: Interventional
- Participants enrolled: 30
- From 19 Mar 2026 to the primary completion date, 21 Apr 2026
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. Expected non-compliance
Who the study is looking for
- Possession of and ability to use a smart phone plus a step counter
- Age ≥18 years
- Written informed consent
- Capacity of the participant to consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Radiation Oncology, University of Luebeck Coordinator of this site? Confirm its status | Lübeck | Germany | Unknown status |
| Department of Oncology Vejle Hospital, University Hospital of Southern Denmark Coordinator of this site? Confirm its status | Vejle | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.